Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Sun Rises For GSK's Trelegy And Shingrix While It Sets For Advair

The drug maker is in the midst of launching several new drugs, including the Shingrix vaccine, the triple COPD therapy Trelegy and the HIV regimen Juluca, hoping new drugs will drive growth as Advair sunsets.

Sales & Earnings Launches Respiratory

Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade

Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.


Clinical Trials Rare Diseases Research & Development

GW CEO: Cannabinoid Platform Is Growth Engine Beyond Epidiolex

Aside from epilepsy in children, GW Pharma also looking to other therapeutic spaces for testing its cannabinoid product candidates, including autism and brain cancer.
Business Strategies Advisory Committees Analysis

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan

All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.

Sales & Earnings Companies Commercial

Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?

WHO’s recommendation around a pre-vaccination screening strategy for Sanofi’s Dengvaxia could potentially dull the prospects of the product further, especially in emerging markets with stretched healthcare resources. One industry expert suggests that governments should probably consider introducing the vaccine only after “better tests and tools” become available.
Commercial Companies Vaccines

As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past

Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.

Pricing Strategies Launches

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Commercial Business Strategies

Takeda Closes In On Shire With Revised £49/Share Offer

Takeda further ups its offer for Shire to around £49 per share, which Shire’s board has said it is willing to recommend to shareholders, although any final deal remains subject to conditions and Takeda investors appear concerned over the size of the transaction.

Japan Commercial

Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch

Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.

Sales & Earnings Neurology

Lilly Rides To Solid First Quarter On Diabetes, Newer Products

Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.
Sales & Earnings Business Strategies

Circassia Puts Aside R&D, Aims To Grow Commercial Platform

UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.


Business Strategies Respiratory

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.

Advisory Committees Drug Safety Inflammation

Kaesong Complex A Starting Point For Two Koreas' Healthcare Cooperation?

As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests. 

South Korea North Korea

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.

Clinical Trials Drug Approval Standards

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

Cancer China

Research & Development Explore this Topic

Set Alert for Research & Development

Spotlight On Israel: Blossoming Targeted Cancer Therapy Startups

Scrip sat down with the CEOs of three emerging oncology companies in Israel that are all focused on targeted cancer treatments, to find out about upcoming milestones and novel technologies that are budding in the country.

Israel Cancer Market Intelligence

InteRNA CEO On Cancer Monotherapy Ambition For Lead Drug

Roel Schaapveld, CEO of InteRNA, chats with Scrip on the sidelines of the 2018 BIO-Europe Spring partnering event about upcoming milestones for the company's RNA pipeline.

Business Strategies Clinical Trials

R&D Successes Celebrated At 2018 CARE Awards

Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.

BioPharmaceutical Research & Development

Advicenne CEO Updates On Phase III Rare Disease Program

Advicenne's CEO Luc-André Granier talks to Scrip about the development journey of its Phase III pediatric-friendly product for a rare renal disease.

Business Strategies Clinical Trials